AppId is over the quota
23 January 2012 Last updated at 08:26 GMT
Frederick Banting discovered insulin by keeping a diabetic dog alive with pancreas extract Insulin has saved the lives of countless people with Type 1 diabetes.In 1921, when the hormone was first discovered by a young Canadian surgeon named Frederick Banting, most children diagnosed with diabetes were expected to die within a year.
Ninety years on and Banting's breakthrough is being hailed a one of the twentieth century's most important medical advances.
Insulin in all its forms continues to ease and prolong the lives of diabetics by keeping blood glucose levels under control.
Sheila Thorn was lucky enough to be treated by Banting in Toronto in 1930 when she was diagnosed as diabetic at just a few months old.
The insulin he prescribed for Sheila has kept her alive for 80 years, making her probably the longest surviving insulin-dependent diabetic in the world.
Continue reading the main storyI've seen a lot of changes in the way people use insulin and these days I use an insulin pump to control my own condition. ”End Quote Sheila Thorn Lucky "I've got a picture of me in mother's arms when we were in Canada. When I was a baby, insulin still wasn't widely available.
"I was lucky enough to be treated by the pioneers of insulin and that's why I'm still here."
Now living in Kent, Sheila remembers being on a very strict diet growing up and her mother injecting her two or three times a day.
"Since then, I've seen a lot of changes in the way people use insulin and these days I use an insulin pump to control my own condition. It makes a world of difference."
Millions of people like Sheila have used various types of synthetically produced insulin to replace the natural insulin that is not produced in people with Type 1 diabetes.
In Toronto in 1921, a severely diabetic dog was the key to Banting's discovery.
Leonard Thompson was the first patient to receive insulin in 1922 Assisted by Charles Best, he kept the dog alive for 70 days by injecting it with a canine pancreas extract.
'Life-saving drug'The first human to benefit from the extract was a 14-year-old boy called Leonard Thompson, who was dying of starvation with diabetes.
Within days his dangerously high blood sugar levels had dropped to near normal levels, and his life was saved.
News of the miracle extract, insulin, spread and soon scientists had clear evidence that it was a life-saving drug.
How insulin can be administered and managed has changed dramatically over the years.
Blood tests, insulin pumps and the many kinds of human and animal insulin now available make it easier to control how much is required by an individual diabetic.
Karen Addington, chief executive of medical research charity, JDRF, says it is still a fine balance.
"Before I got an insulin pump, I had to take a precise dose of insulin and calculate the carbs I was eating and also things like exercise and stress, which can also have an impact. I was always juggling things around."
With an insulin pump delivering a varied dose of insulin continually throughout the day and night, Karen says it mimics the working of the pancreas in someone who does not have diabetes.
But it still doesn't test blood glucose levels or work out how much insulin to deliver.'Mechanical cure'The future promises two ways of getting round these problems, which could revolutionise life for diabetics.
The first is an 'artificial pancreas', essentially an insulin pump linked to a blood sugar monitor which is worn externally and is the size of a thumbnail.
"It will mean no hypos and hypers and no complications for people with Type 1 like strokes, amputations or blindness.
"It's a mechanical cure."
The second product being invested in by JDRF is a molecule which sits on the fingertips of the patient, releasing insulin into the blood whenever it is needed.
"The pace of development in Type 1 diabetes is really amazing," say Addington, who hopes that trials of both devices will lead to general use in a few years or so.
But Barbara Young, from Diabetes UK, still believes more should and could be done to manage both Type 1 and Type 2 diabetes.
"Diabetes is seen as a less serious disease than cancers and strokes, but you can die from it too.
"Perhaps because it's a long-term condition, there's a lack of political will to properly manage and educate patients so that complications and hospital admissions are avoided."
Young cites the example of insulin pumps, which only 3.9% of people with Type 1 diabetes have access to in the UK because of "a postcode lottery and a lack of funding".
Amy Turner, who is 28, knows what it is like to have Type 1 diabetes but no pump to help her, especially since she is a keen runner.
"It is not easy but I have to adapt and plan ahead. I never go out with a bag full of extra sugar if I need it.
"I am sadly not eligible for an insulin pump, although the doctors can see how it would benefit me."
Yet, Amy is determined that her diabetes will not get in the way of her life.
"I would have died it it hadn't been for insulin. With the different types of insulin now, I can do what I want to do. I want to prove I can do physical things like half marathons."
Frederick Banting would be proud. But Amy has the final word.
"Insulin is a life-saver, but it's not a cure, just a treatment."
GOOGLE NEWS | BBC NEWS | NY DAILY NEWS | TRAFFIC NEWS | TECH NEWS





Surprising results from two new studies may reopen debate about the value of Avastin for breast cancer. The drug helped make tumors disappear in certain women with early-stage disease, researchers found.Avastin recently lost approval for treating advanced breast cancer, but the new studies suggest it might help women whose disease has not spread so widely. These were the first big tests of the drug for early breast cancer, and doctors were cautiously excited that it showed potential to help.In one study, just over one third of women given Avastin plus chemotherapy for a few months before surgery had no sign of cancer in their breasts when doctors went to operate, versus 28 percent of women given chemo alone. In the other study, more than 18 percent on Avastin plus chemo had no cancer in their breasts or lymph nodes at surgery versus 15 percent of those on chemo alone.A big caveat, though: The true test is whether Avastin improves survival, and it's too soon to know that — both studies are still tracking the women's health. The drug also has serious side effects."I don't think it's clear yet whether this is going to be a winner," Dr. Harry Bear of Virginia Commonwealth University said of Avastin. But he added, "I don't think we're done with it."Bear led one study, in the United States. Dr. Gunter von Minckwitz of the University of Frankfurt led the other in Germany. Results are in Thursday's New England Journal of Medicine.Avastin (uh-VAS'-tihn) is still on the market for some colon, lung, kidney and brain tumors. In 2008, it won conditional U.S. approval for advanced breast cancer because it seemed to slow the disease. Further research showed it didn't meaningfully extend life and could cause heart problems, bleeding and other problems. The government revoked its approval for breast cancer in November.Now doctors can prescribe Avastin for breast cancer but insurers may not pay. Treatment can cost $10,000 a month. The drug is made by California-based Genentech, part of the Swiss company Roche. It is still approved for treating advanced breast cancer in Europe and Japan.The new studies tested it in a relatively novel way — before surgery. This is sometimes done to shrink tumors that seem inoperable, or to enable women to have just a lump removed instead of the whole breast.The women in the studies had tumors that were large enough to warrant treatment besides surgery. Their cancers were not the type that can be treated by Herceptin, another widely used drug.In the U.S. study, 1,200 women were given chemo or chemo plus infusions of Avastin. By the time of their surgery, no cancer could be found in the breasts of more than 34 percent of those given Avastin versus 28 percent of the others. (Surgeons still have to operate because they don't know the tumor is gone until they check tissue samples.)The German study involved 1,900 women including some with larger tumors. It used a stricter definition of cancer-free at surgery: no sign of disease in the breast or lymph nodes rather than just the breast. No cancer was seen in 18 percent of women on Avastin versus 15 percent of those given only chemo. Different chemo drugs were used — a factor that might change Avastin's effectiveness.The U.S. study was paid for by the National Cancer Institute with some support from drug companies. The German study was sponsored by drug companies. Some researchers consult for Genentech or other makers of cancer drugs.If even one of these studies shows a survival advantage for Avastin "that would be a game changer" although side effects remain a concern, said Dr. Gary Lyman. He is a Duke University researcher who was on the federal advisory panel that recommended revoking Avastin's approval.However, von Minckwitz said side effects are more justifiable in early breast cancer patients because "the intention is cure" rather than in late-stage disease where cure isn't usually possible.Of the more than 200,000 women in the U.S. diagnosed each year with breast cancer, about 30,000 are like those in the new studies, Lyman estimated.But the studies' impact could be far greater: The participants' tissue samples are being analyzed for genes and biomarkers to predict which women are most likely to respond to Avastin. That could lead to a relook of using the drug for certain women with advanced disease, too.Three other studies are under way testing Avastin in early breast cancer; one is expected to have results by the end of this year, said Dr. Sandra Horning, global development chief of cancer drugs for Roche and Genentech. The company does not plan to seek any change in Avastin's use until more results are available, she said.___Online:Studies: http://www.nejm.orgAvastin: http://www.avastin.com___Marilynn Marchione can be followed at http://twitter.com/MMarchioneAPAssociated Press
Jenni ist in einer Beziehung mit Tim, wer nicht asexuelle Twenty-one-Year-Old Jenni Goodchild ist erlebt nicht sexuelle Anziehung, aber in einer zunehmend sexualisierte Gesellschaft wie ist es zu asexuelle?

